摘要
目的:探究结直肠癌(CRC)患者血浆中miR-221的临床价值。方法:收集60例正常健康体检志愿者(对照组),80例就诊我院的CRC患者(病例组),对所有入选者均进行血浆miR-221实时荧光定量聚合酶链反应(real time-PCR)检测。结果:(1)血浆miR-221含量在CRC组织较对照组表达明显升高(P<0.001),并随着duke分期的发展呈现递增的趋势(P<0.01)。(2)患者入院后均符合手术治疗条件,并于术后第7天复查miR-221含量,发现较治疗前明显减低(P<0.01)。3.对入院时CRC患者根据血浆miR-221相对值进行分组,miR-221高值组术后2年内发生癌复发的发生率高于低值组(P<0.001)。结论:血浆miR-221的测定有助于CRC的诊断,并对病情的估计和预后的判断有一定的帮助。
Objective: To investigate the clinical significance of miR-221 in plasma from patients with colorectal cancer(CRC).Methods: The plasma levels of miR-221 from 60 healthy controls and 80 patients with CRC were measured by real-time reverse transcription-polymerase chain reaction(real time-PCR).Results: 1.The plasma levels of miR-221 were markedly higher in CRC group than in controls group,which showed increasing trends with the development of the duke stage.2.Patients were in line with surgical treatment conditions and the plasma levels of miR-221 were detected in the seventh day after surgical treatment.There was a significant difference between patients before treatment and after treatment.3.The CRC patients were grouped by the relative plasma levels of miR-221,the incidence of cancer recurrence was higher in group with high plasma levels of miR-221 than that in group with lower level within 2 years after surgery.Conclusion: The plasma levels of miR-221 are helpful to diagnose CRC and judge the progression and prognosis of the disease.
出处
《中国卫生检验杂志》
北大核心
2012年第3期517-519,共3页
Chinese Journal of Health Laboratory Technology
基金
国家自然科学基金(81000176/H0317)
浙江省自然科学基金(Y2090326)
王宝恩肝纤维化研究基金(20100002)
温州市科技局(Y20110033)